Biopharmaceutical company Navidea Biopharmaceuticals Inc (NYSE American:NAVB) Friday disclosed an extension of the Lymphoseek patent, which has been assigned US patent 6,409,990, for an additional five years.
The US Food and Drug Administration (FDA) has reportedly released a letter indicating that the US Patent and Trademark Office (USPTO) is allowed to extend Lymphoseek's patent for an additional five years or until 12 May 2025.
In conjunction, the patent claims Lymphoseek (technetium (Tc 99m) tilmanocept) has been exclusively licensed with varying geographical and medical indication coverages to Cardinal Health and Navidea.
Following the allowance of this patent extension, Cardinal Health and Navidea will extend their exclusive rights to manufacture and commercialise Lymphoseek until the end of the extended patent term in 2025.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval